We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 20, 2019

Immune Checkpoint Inhibitors Improves the Response to Salvage Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

European Journal of Cancer

 

Additional Info

European Journal of Cancer
Response to Salvage Chemotherapy After Progression on Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Eur. J. Cancer 2019 Nov 01;121(xx)123-129, K Saleh, A Daste, N Martin, E Pons-Tostivint, A Auperin, RG Herrera-Gomez, N Baste-Rotllan, F Bidault, J Guigay, C Le Tourneau, E Saada-Bouzid, C Even

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading